Indication intelligence, analysis and sector perception

RegMed Investors (RMI): burning investors, Applied Genetic Technologies (AGTC)

August 30, 2022 7:51am

AGTC closed flat at $0.42 on Monday with 866,956 shares traded after Friday -$0.006 to $0.42 with 398,300 shares traded, following 1/3/22’s $2.06 with 398, shares traded and 8/30/21’s $3.54 with 279,200 shares traded.

Pre-open indication: -$0.02

An utter CEO share pricing failure, while Sue Washer, CEO and President of Applied Genetic Technologies (AGTC) got a 2022 $185,055 bonus to her salary of $575,000.00 <8-K dated 8/26/22>. Looking back at share pricing history WHY does she deserve a bonus?

Investors are co-owners; she needs and MUST step-down or be replaced.

Also, investors should know about the toll of exiting employees, and severe problems with recruiting qualified management due to her management – serious investors won’t touch this PIG!

866,956 shares traded in one (1) day <3-month average = 1.256 M shares> defines dissatisfaction – KEEP selling, more shareholders need to STEP-UP to NOTICE this board of directors (BOD) and show non-support of this CEO!

Maybe she should consider spending her bonus on the company’s stock – INVEST or can’t you take the losses we investors have taken – I remember the stock price at $7.21!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

10 hours 11 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.